All Access Articles |
- Axsome Therapeutics Reports $191.2M Net Revenue Growth | 2026-05-04 | UNITED STATES
- FDA Approves Axsome Therapeutics' Auvelity for Agitation in Alzheimer's Disease | 2026-05-01 | UNITED STATES
- Axsome Therapeutics Acquires Balipodect for Schizophrenia and Tourette Syndrome | 2026-04-01 | UNITED STATES
- Axsome Therapeutics (AXSM) Reports 65% Growth in Net Product Revenue | 2026-02-23 | UNITED STATES
- FDA Rejects Axsome's Fibromyalgia Drug Application | 2025-06-09 | PHARMACEUTICAL
- Axsome Therapeutics settles patent litigation on Sunosi | 2025-05-27 | PHARMACEUTICAL
- Axsome Therapeutics Reports 62% Growth in Q1 Revenue | 2025-05-05 | PHARMACEUTICAL
- Axsome Therapeutics reports mixed results from Paradigm trial | 2025-04-01 | PHARMACEUTICAL